Precipio

Precipio, Inc.is a cancer diagnostics and reagent technology company, which provides diagnostic products and services to the oncology market. Its products include ICP, HemeScreen, and IV-Cell, and services include primary diagnostic, SmartPath, SmartGen, HemeScreen Panel, and ICE COLD-PCR. The company was founded on March 6, 1997 and is headquartered in New Haven, CT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Precipio (PRPO) reports revenue growth and aims for profitability

Precipio's Q2 performance reflects positive momentum in revenue growth and operational improvements. While challenges like achieving profitability and FDA approval exist, the company's focus on building relationships and scaling up presents opportunities for future growth. Overall, Precipio is well-positioned to achieve its goals and enhance investor relations post-profitability.

Precipio (PRPO) achieves record diagnoses, nears breakeven in Q3 2024

Precipio's Q3 2024 earnings call highlights strong revenue growth, progress towards breakeven, and improved financial stability. While facing challenges in investor relations, the company's focus on education and visibility initiatives shows a proactive approach to addressing concerns. Leveraging key customer relationships and sustainable growth strategies offer promising opportunities for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Precipio stock rocketed higher for a second session on Tuesday, with a fivefold surge in the price ignited after the specialty diagnostics company launched its COVID-19 antibody test on Amazon.  The company said it holds the exclusive rights to distribute the 20-minute test on Amazon's platform. Precipio said the test, which covers two types of antibodies, was visible for sale on the retailing giant's website and app.

Precipio extends 2-day gain to 404% following launch of the company's COVID-19 test on Amazon

Precipio Inc (NASDAQ: PRPO) is rallying again on Tuesday after it announced Monday the company successfully launched its COVID-19 rapid antibody test on the Amazon.com Inc (NASDAQ: AMZN) platform. What Happened: Precipio announced the launch of its 20-minute COVID-19 antibody test on Amazon and the stock soared more than 140%.

Why Precipio's Stock Is Moving Higher Today

American Shared Hospital Services

Milestone Scientific

TOP Ships

Looking for penny stocks to watch in May? Look no further The post 4 Hot Penny Stocks To Watch In May 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Hot Penny Stocks To Watch In May 2021

The stock price of Precipio Inc (NASDAQ: PRPO) increased from $4.95 to $6.23 pre-market. This is why it happened.

PRPO Stock: From $4.95 To $6.23 (25.86% Increase) Pre-Market Explanation

Shares of microcap Precipio Inc. , a specialty diagnostics company, soared 41% in premarket trade Tuesday, adding to gains of more than 170% on Monday, after the company said its COVID-19 rapid antibody test is now available on Amazon.com's business platform. The 20-minute test, which was awarded emergency use authorization from the U.S. Food and Drug Administration in December, can only be purchased by qualified medical point-of-care providers.

Shares of medical diagnostics company Precipio soar 40% premarket as rapid COVID test available on Amazon

The stock price of Precipio Inc (NASDAQ: PRPO) increased by 37.17% during after-hours trading as it went from $4.95 to $6.79. This is why it happened.

PRPO Stock: From $4.95 To $6.97 (37.17% Increase) After Hours Explanation

Precipio Inc. (NASDAQ: PRPO) shares surged 140% Monday after the company successfully launched its COVID-19 rapid antibody test that tests for both IgG & IgM antibodies. Testing for antibodies will let people know if they have previously been exposed to the virus or have been vaccinated.

Precipio Surges 140%, Breaks Out Of A Falling Wedge Pattern

Precipio (PRPO) is launching its rapid COVID-19 antibody test for sale on Amazon (AMZN) and its stock is soaring on the news. The post PRPO Stock: 12 Things to Know about the Precipio Rapid COVID-19 Antibody Test Launch on Amazon appeared first on InvestorPlace.

PRPO Stock: 12 Things to Know about the Precipio Rapid COVID-19 Antibody Test Launch on Amazon

The stock price of Precipio Inc (NASDAQ: PRPO) increased from a previous close of $1.82 to a day high of $2.50 (up 37.36%) during intraday trading this morning. This is why it happened.

PRPO Stock: From $1.82 To $2.50 Intraday Explanation

PPRO Stock: From $1.82 To $2.50 Intraday Explanation

Nirmidas' test is available to POC healthcare providers with an Amazon business account Nirmidas' test is available to POC healthcare providers with an Amazon business account

Precipio Launches its Rapid COVID-19 Antibody test on Amazon Platform

Precipio reaffirms forecast that product revenues will reach approximately 50% of pathology revenue by the fourth quarter of 2021 Precipio reaffirms forecast that product revenues will reach approximately 50% of pathology revenue by the fourth quarter of 2021

Current Signed Customers Expected to Generate $1M Annualized Reported Revenues from Precipio's HemeScreen POL Offering by Q4-2021

NEW HAVEN, Conn., April 05, 2021 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO) , announces a new “At-The-Market” (ATM) financing arrangement that improves its financing flexibility. As provided in the Company's prospectus supplement filed on April 2, 2021, Precipio will be able to sell shares from time to time through the ATM offering, up to an aggregate of $20M. The Company anticipates that this will be its primary financing method going forward.

Precipio Enters Into an At-The -Market (ATM) Financing Arrangement

Precipio, Inc. (PRPO) CEO Ilan Danieli on Q4 2020 Results - Earnings Call Transcript

The stock price of Precipio, Inc. (NASDAQ: PRPO) increased by over 5% pre-market. This is why it happened.

PRPO Increased Over 5% Pre-Market: Why It Happened

HemeScreen projected to rapidly become a material revenue contributor in 2021 HemeScreen projected to rapidly become a material revenue contributor in 2021

Precipio Announces 95% Annual Growth YoY and 180% Quarterly Growth YoY

Conference Call to be held on Wednesday, March 31st, 2021 at 5:00 PM EST Conference Call to be held on Wednesday, March 31st, 2021 at 5:00 PM EST

Precipio Announces Q4-2020 and year-end Shareholder Update Call

Company Strengthens Depth of Expertise in Products Industry Company Strengthens Depth of Expertise in Products Industry

Mr. Ron Andrews joins Precipio's Board of Directors

NEW HAVEN, Conn., March 03, 2021 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company  Precipio, Inc.   (NASDAQ: PRPO) announces the appointment of Mr. Richard Sandberg as Chairman of the Board of Directors. Dr. Douglas Fisher will step down as Chairman and maintain his role as a Director on the company's board.

Mr. Richard Sandberg is appointed Chairman of Precipio's Board of Directors

Following the receipt of FDA EUA by Nirmidas, Precipio begins market roll out to POC Following the receipt of FDA EUA by Nirmidas, Precipio begins market roll out to POC

Precipio Launches COVID-19 Antibody Testing at Point-of-Care

Partnership with ION Solutions expected to accelerate sales Partnership with ION Solutions expected to accelerate sales

Precipio Signs HemeScreen™ Deals with Two Leading Oncology Groups

Thousands of Oncology Practices will gain access to HemeScreen POL program Thousands of Oncology Practices will gain access to HemeScreen POL program

Precipio Signs Sales & Marketing Agreement for HemeScreen™ with Major Oncology Distributor

Precipio, Inc. (PRPO) CEO Ilan Danieli on Q3 2020 Results - Earnings Call Transcript

Conference Call to be held on Thursday, November 19th, 2020 at 5:00 PM EST Conference Call to be held on Thursday, November 19th, 2020 at 5:00 PM EST

Precipio Announces Q3-2020 Shareholder Update Call

Prominent Laboratories in US and Europe will begin testing the media Prominent Laboratories in US and Europe will begin testing the media

News for Precipio Stock (PRPO)